Cargando…

REDD1 promotes obesity-induced metabolic dysfunction via atypical NF-κB activation

Regulated in development and DNA damage response 1 (REDD1) expression is upregulated in response to metabolic imbalance and obesity. However, its role in obesity-associated complications is unclear. Here, we demonstrate that the REDD1–NF-κB axis is crucial for metabolic inflammation and dysregulatio...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, Dong-Keon, Kim, Taesam, Byeon, Junyoung, Park, Minsik, Kim, Suji, Kim, Joohwan, Choi, Seunghwan, Lee, Gihwan, Park, Chanin, Lee, Keun Woo, Kwon, Yong Jung, Lee, Jeong-Hyung, Kwon, Young-Guen, Kim, Young-Myeong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9588012/
https://www.ncbi.nlm.nih.gov/pubmed/36272977
http://dx.doi.org/10.1038/s41467-022-34110-1
Descripción
Sumario:Regulated in development and DNA damage response 1 (REDD1) expression is upregulated in response to metabolic imbalance and obesity. However, its role in obesity-associated complications is unclear. Here, we demonstrate that the REDD1–NF-κB axis is crucial for metabolic inflammation and dysregulation. Mice lacking Redd1 in the whole body or adipocytes exhibited restrained diet-induced obesity, inflammation, insulin resistance, and hepatic steatosis. Myeloid Redd1-deficient mice showed similar results, without restrained obesity and hepatic steatosis. Redd1-deficient adipose-derived stem cells lost their potential to differentiate into adipocytes; however, REDD1 overexpression stimulated preadipocyte differentiation and proinflammatory cytokine expression through atypical IKK-independent NF-κB activation by sequestering IκBα from the NF-κB/IκBα complex. REDD1 with mutated Lys(219/220)Ala, key amino acid residues for IκBα binding, could not stimulate NF-κB activation, adipogenesis, and inflammation in vitro and prevented obesity-related phenotypes in knock-in mice. The REDD1-atypical NF-κB activation axis is a therapeutic target for obesity, meta-inflammation, and metabolic complications.